The Pilot Clinical Trial Award (PCTA) supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based, innovative interventions that have the potential to result in a profound impact on the management of MS symptoms.
While therapeutic approaches proposed for testing through the PCTA must represent novel, hypothesis-based approaches for treating MS symptoms, they may include therapies already in clinical use, or undergoing clinical testing for other diseases, provided that their proposed use for MS would lead to a major advancement for treating one of the disease symptoms.
Proposals must address the treatment of MS Symptoms, which may include: Pain, Fatigue, Cognitive Dysfunction, Visual Impairment, Motor Impairment, Impaired Mobility, Loss of Bladder Control, Sexual Dysfunction, Depression, and Anxiety.
Funding & Duration
The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed US $600,000 (approx. AUD $770,000).
Funding may be used for salary, research supplies, research-related subject costs, clinical research costs, travel between collaborating organisations, travel costs for up to 2 investigators to travel to 1 scientific/technical meeting per year.
Preclinical research studies are not eligible for funding.
The Primary Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent).
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Dates
- 26 May 2016 – pre-proposal submitted via https://eBRAP.org.
- Copy of pre-proposal forwarded to the Research Branch ASAP.
- 15 August 2016 – full applications (by invitation only) submitted to the Research Branch for internal review.
- Grants Officer: Dr Don McMaster
- Email: firstname.lastname@example.org